Hastings Paul J
SEC-identified person · CIK 1309702 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Nkarta, Inc. NKTX | Director · See Remarks | filed 2020 - 2026 |
| Engene Therapeutics Inc. ENGN | Director | filed 2024 - 2026 |
| Pacira Pharmaceuticals, Inc. PCRX | Director | filed 2011 - 2024 |
| Protara Therapeutics, Inc. TARA | Director | filed 2016 - 2018 |
| Oncomed Pharmaceuticals Inc OMED | Director · President & CEO | filed 2013 - 2017 |
| Relypsa Inc RLYP | Director | filed 2013 - 2016 |
| Viacell INC VIAC | Director | filed 2006 - 2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.